Prakash Manoharan

Dr. Prakash Manoharan


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 August 2024 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
MDMichael J. Dubec
Michael J. Dubec
JPJames Price
James Price
MBMichael Berks
Michael Berks
JGJohn Gaffney
John Gaffney
RLRoss A. Little
Ross A. Little
James P B O'ConnorJames P B O'Connor
James P B O'Connor
Purpose: Hypoxia mediates treatment resistance in solid tumors. We evaluated if oxygen-enhanced MRI–derived hypoxic volume (HVMRI) is repeatable and can detect radiotherapy-induced hypoxia modification in human papillomavirus–associated oropharyngeal head and neck squamous cell cancer. Experimental Design: A total of 27 patients were recruited prospectively between March 2021 and January 2024. HVMRI was measured in primary and nodal tumors prior to standard-of-care (chemo)radiotherapy and then at weeks 2 and 4 (W2 and W4) into therapy. Two pretreatment scans assessed biomarker within-subject coefficient of variation and repeatability coefficient (RC). Cohort treatment response was measured using mixed-effects modeling. Responding lesions were identified by comparing HVMRI change with RC limits of agreement. Results: Oxygen-enhanced MRI identified hypoxia in all lesions. The HVMRI within-subject coefficient of variation was 24.6%, and RC limits of agreement were −45.7% to 84.1%. A cohort median pretreatment HVMRI of 11.3 cm3 reduced to 6.9 cm3 at W2 and 5.9 cm3 at W4 (both P < 0.001). HVMRI was reduced in 54.5% of individual lesions by W2 and in 88.2% by W4. All lesions with W2 hypoxia reduction showed persistent modification at W4. HVMRI reduced in some lesions that showed no overall volume change. Hypoxia modification was discordant between primary and nodal tumors in 50.0% of patients. Conclusions: Radiation-induced hypoxia modification can occur as early as W2, but onset varies between patients and was not necessarily associated with overall size change. Half of all patients had discordant changes in primary and nodal tumors. These findings have implications for patient selection and timing of dose de-escalation strategies in human papillomavirus–associated oropharyngeal carcinoma. See related commentary by Mason, p. 5503

20 July 2022 in Current Oncology
Verified
Journal Article
Open access
PDF file
ZKZainul Abedin Kapacee
Zainul Abedin Kapacee
JAJennifer Allison
Jennifer Allison
MDMohammed Dawod
Mohammed Dawod
XWXin Wang
Xin Wang
MFMelissa Frizziero
Melissa Frizziero
MMMairead Mcnamara
Mairead Mcnamara
Background: Brain metastases (BMs) in patients with extra-pulmonary neuroendocrine neoplasms (EP–NENs) are rare, and limited clinical information is available. The aim of this study was to detail the clinicopathological features, management and outcomes in patients with EP–NENs who developed BMs. Methods: A retrospective single-centre analysis of consecutive patients with EP–NENs (August 2004–February 2020) was conducted. Median overall survival (OS)/survival from BMs diagnosis was estimated (Kaplan–Meier). Results: Of 730 patients, 17 (1.9%) had BMs, median age 61 years (range 15–77); 8 (53%) male, unknown primary NEN site: 40%. Patients with BMs had grade 3 (G3) EP–NENs 11 (73%), G2: 3 (20%), G1: 1 (7%). Eight (53%) had poorly differentiated NENs, 6 were well-differentiated and 1 was not recorded. Additionally, 2 (13%) patients had synchronous BMs at diagnosis, whilst 13 (87%) developed BMs metachronously. The relative risk of developing BMs was 7.48 in patients with G3 disease vs. G1 + G2 disease (p = 0.0001). Median time to the development of BMs after NEN diagnosis: 15.9 months (range 2.5–139.5). Five patients had a solitary BM, 12 had multiple BMs. Treatment of BMs were surgery (n = 3); radiotherapy (n = 5); 4: whole brain radiotherapy, 1: conformal radiotherapy (orbit). Nine (53%) had best supportive care. Median OS from NEN diagnosis was 23.6 months [95% CI 15.2–31.3]; median time to death from BMs diagnosis was 3.0 months [95% CI 0.0–8.3]. Conclusion: BMs in patients with EP–NENs are rare and of increased risk in G3 vs. G1 + G2 EP–NENs. Survival outcomes are poor, and a greater understanding is needed to improve therapeutic outcomes.

9 March 2026 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Open access
ADAnubhav Datta
Anubhav Datta
WSWilliam Spiller
William Spiller
HMHitesh Mistry
Hitesh Mistry
PJPeter Julyan
Peter Julyan
JOJames Pb O’COnnor
James Pb O’COnnor
PMPrakash Manoharan
Prakash Manoharan
The prognostic value of baseline 18F-FDG PET/CT-derived metrics in limited-stage small-cell lung cancer (LS-SCLC) remains uncertain. We evaluated whether baseline PET-derived parameters provide prognostic information beyond tumour volume and clinical factors in patients treated with curative-intent chemoradiotherapy within the phase III CONVERT trial. CONVERT was an international, multi-centre randomised controlled trial. This study is a post-hoc analysis of baseline 18F-FDG PET/CT from the multiple PET imaging parameter (MPI) cohort across 8 UK sites. PET metrics, including whole-body metabolic tumour volume (MTV), total lesion glycolysis (TLG), SUV-based measures, and radiomic features, were derived under EARL-accredited conditions. CT-derived gross tumour volume (GTV) and a pre-specified clinical prognostic model (CPM) were assessed alongside PET metrics. Overall survival (OS) and progression-free survival (PFS) were analysed using Cox regression. Incremental prognostic value beyond CPM was evaluated using Harrell’s concordance index (C-index). Correlations between imaging, clinical, and circulating tumour cell (CTC) variables were explored. Ninety-four patients comprised the MPI cohort. In univariable analyses, CPM, CT-GTV, and PET-derived MTV and TLG, were associated with shorter OS and PFS. After multivariable adjustment, only CT-GTV remained independently prognostic for OS (HR 1.36, 95% CI 1.06–1.74) and PFS (HR 1.29, 95% CI 1.03–1.63). CPM demonstrated moderate prognostic discrimination (C-index 0.63 for OS; 0.59 for PFS). Addition of SUV-based PET metrics did not improve discrimination beyond CPM (ΔC-index ≤ 0.002). PET-derived volumetric parameters were strongly correlated with CT-GTV and CPM, indicating redundancy. Circulating tumour cell counts, available in a subset, showed no significant correlations. In LS-SCLC treated with curative-intent chemoradiotherapy, baseline tumour volume is the dominant prognostic determinant. Baseline 18F-FDG PET-derived metabolic and radiomic parameters do not provide meaningful incremental prognostic value beyond tumour burden and clinical factors. While PET/CT remains essential for staging and treatment selection, its role in baseline prognostic stratification appears limited. The online version contains supplementary material available at 10.1007/s00259-026-07812-7.

18 December 2024
Verified
Other
Open access
MDMichael J. Dubec
Michael J. Dubec
JPJames Price
James Price
MBMichael Berks
Michael Berks
JGJohn Gaffney
John Gaffney
RLRoss A. Little
Ross A. Little
James P B O'ConnorJames P B O'Connor
James P B O'Connor
Treatment-induced changes in OE-MRI–derived biomarkers. A, Example hypoxia maps for a large metastatic lymph node (patient 7) obtained at two BL timepoints (BL0 and BL1) and W2 and W4 of radiation treatment. Corresponding ΔR1 maps are provided in Supplementary Fig. S7A–S7C. B, Bar charts plot the relative sizes of HVMRI along with NVMRI and nonperfused volume for this patient. Note: The combination of HVMRI, NVMRI, and nonperfused volume equate to the WTV. C, Patient cohort assessment of treatment effects illustrated as plots of standard error of the mean (SEM) for (top left to bottom right) HVMRI, NVMRI, nonperfused volume, WTV, HFMRI, and ΔR1.

18 December 2024
Verified
Other
Open access
MDMichael J. Dubec
Michael J. Dubec
JPJames Price
James Price
MBMichael Berks
Michael Berks
JGJohn Gaffney
John Gaffney
RLRoss A. Little
Ross A. Little
James P B O'ConnorJames P B O'Connor
James P B O'Connor
Supplementary Figure S7. Treatment-induced changes in OE-MRI biomarker ΔR1.

18 December 2024
Verified
Other
Open access
MDMichael J. Dubec
Michael J. Dubec
JPJames Price
James Price
MBMichael Berks
Michael Berks
JGJohn Gaffney
John Gaffney
RLRoss A. Little
Ross A. Little
James P B O'ConnorJames P B O'Connor
James P B O'Connor
Supplementary Table S4. Summary of cohort lesion parameter median values at baseline and W2 and W4.